Mohammad Ullah Nayan
Overview
Explore the profile of Mohammad Ullah Nayan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Edagwa B, Nayan M, Sillman B, Das S, Hanson B, Sultana A, et al.
Res Sq
. 2025 Mar;
PMID: 40034436
Ultra-long-acting (ULA) antiretroviral parenteral formulations, with low injection volumes, high resistance barriers, and short pharmacokinetic (PK) tails, can transform HIV-1 therapeutics. Here, we converted bictegravir (BIC), a potent daily oral...
2.
Islam F, Das S, Ashaduzzaman M, Sillman B, Yeapuri P, Nayan M, et al.
Commun Biol
. 2024 Jul;
7(1):917.
PMID: 39080401
An extended action fostemsavir (FTR) lipid nanoparticle (LNP) formulation prevents human immunodeficiency virus type one (HIV-1) infection. This FTR formulation establishes a drug depot in monocyte-derived macrophages that extend the...
3.
Nayan M, Panja S, Sultana A, Zaman L, Vora L, Sillman B, et al.
Pharmaceutics
. 2024 Feb;
16(2).
PMID: 38399244
The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency...
4.
Kevadiya B, Islam F, Deol P, Zaman L, Mosselhy D, Ashaduzzaman M, et al.
Nanomedicine
. 2023 Oct;
54:102711.
PMID: 37813236
For the past decades, gene editing demonstrated the potential to attenuate each of the root causes of genetic, infectious, immune, cancerous, and degenerative disorders. More recently, Clustered Regularly Interspaced Short...
5.
Ogunnaike M, Das S, Raut S, Sultana A, Nayan M, Ganesan M, et al.
Biomolecules
. 2023 Aug;
13(8).
PMID: 37627273
Chronic hepatitis B virus (HBV) infection leads to the development of cirrhosis and hepatocellular carcinoma. Lifelong treatment with nucleotides/nucleoside antiviral agents is effective at suppressing HBV replication, however, adherence to...
6.
Nayan M, Sillman B, Hasan M, Deodhar S, Das S, Sultana A, et al.
Adv Drug Deliv Rev
. 2023 Jul;
200:115009.
PMID: 37451501
Adherence to daily oral antiretroviral therapy (ART) is a barrier to both treatment and prevention of human immunodeficiency virus (HIV) infection. To overcome limitations of life-long daily regimen adherence, long-acting...
7.
Shahjin F, Patel M, Machhi J, Cohen J, Nayan M, Yeapuri P, et al.
Acta Biomater
. 2022 Dec;
158:493-509.
PMID: 36581007
Effective antigen delivery facilitates antiviral vaccine success defined by effective immune protective responses against viral exposures. To improve severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antigen delivery, a controlled biodegradable, stable,...
8.
Shahjin F, Patel M, Hasan M, Cohen J, Islam F, Ashaduzzaman M, et al.
Nanomedicine
. 2022 Dec;
48:102644.
PMID: 36549555
Porous polymer microspheres are employed in biotherapeutics, tissue engineering, and regenerative medicine. Porosity dictates cargo carriage and release that are aligned with the polymer physicochemical properties. These include material tuning,...